BackIntelligent Medicine Acquisition Overview
Intelligent Medicine Acquisition Corp - Class A

Intelligent Medicine Acquisition Return on Equity

Intelligent Medicine Acquisition (IQMD) has a ROE of 2157193.89%, above the sector sector average of 11.85%.

Get informed when a big investor buys or sells

+ Follow

ROE

2157193.89%

Return on Equity

2157193.89%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Intelligent Medicine Acquisition (IQMD) FAQ

The latest ROE for IQMD is 2157193.89%. That is above the sector sector average of 11.85%. Investors often review this figure alongside Intelligent Medicine Acquisition's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, IQMD currently prints 2157193.89% for ROE, while the sector average sits near 11.85%. That is roughly 18200696.9% above the sector mean. Large gaps often invite a closer look at Intelligent Medicine Acquisition's growth, margins, and balance sheet.

Return on Equity shows how effectively Intelligent Medicine Acquisition converts resources into returns. At 2157193.89%, IQMD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IQMD's ROE (2157193.89%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.